Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares for approximately $5.08 million at an average price of $534.66, reducing her ownership by 2.84% to 324,443 shares.
- United Therapeutics reported quarterly EPS of $7.27, exceeding the $6.86 consensus estimate, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Analysts maintain a “Moderate Buy” consensus with an average price target of $650, while institutional investors own 94.08% of the company’s shares.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, October 16th. The stock was sold at an average price of $534.66, for a total value of $5,079,270.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $173,466,694.38. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
United Therapeutics Trading Up 1.9%
NASDAQ UTHR opened at $543.15 on Tuesday. The company has a fifty day simple moving average of $513.91 and a 200 day simple moving average of $539.71. United Therapeutics Corporation has a 12-month low of $409.07 and a 12-month high of $609.35. The company has a market cap of $23.30 billion, a P/E ratio of 19.43, a PEG ratio of 3.81 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. During the same quarter in the prior year, the company posted $6.41 earnings per share. The business's revenue was down 1.9% on a year-over-year basis. Sell-side analysts predict that United Therapeutics Corporation will post 26.40 EPS for the current year.
Hedge Funds Weigh In On United Therapeutics
Hedge funds have recently bought and sold shares of the company. Toth Financial Advisory Corp raised its holdings in shares of United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 48 shares during the last quarter. Fiduciary Financial Advisors bought a new position in shares of United Therapeutics during the second quarter valued at about $30,000. Caitlin John LLC purchased a new position in United Therapeutics during the second quarter worth about $37,000. International Assets Investment Management LLC boosted its holdings in United Therapeutics by 426.7% during the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 64 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. purchased a new position in United Therapeutics during the second quarter worth about $81,000. 94.08% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
UTHR has been the topic of a number of analyst reports. Bank of America lowered their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. JPMorgan Chase & Co. lifted their price target on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. Jefferies Financial Group reissued a "buy" rating and set a $728.00 price objective on shares of United Therapeutics in a report on Wednesday, October 14th. The Goldman Sachs Group reissued a "sell" rating and issued a $368.00 price objective on shares of United Therapeutics in a research note on Thursday. Finally, UBS Group set a $725.00 price objective on United Therapeutics in a research note on Monday. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $650.00.
Check Out Our Latest Analysis on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company's portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.
The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
